Mahmoud Ghazzi joins Daiichi Sankyo
As executive vice president of drug development for the Americas
DSPD, headquartered in Edison, NJ, runs clinical trials throughout the region and Ghazzi will work closely with the global development regional heads in Asia, Japan and Europe to ensure delivery of clinical development programmes.
He will oversee critical regional functions such as clinical development, regulatory affairs, translational medicine and clinical pharmacology and clinical safety and pharmacovigilance. He also be co-chairman of the Daiichi Sankyo Global Clinical Committee, which ensures that all programmes meet the highest standards.
Prior to joining DSPD, Ghazzi served in roles of increasing responsibility at GlaxoSmithKline (GSK) and Pfizer where he developed and managed clinical trials for cardiovascular, metabolism, obesity and diabetes drugs.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Looking ahead to a challenging year
Asia is emerging as a rival to the US as a leading source of drug discovery and high end innovation. Both clinical trials activity and investments by drug majors are set to expand in Asia, with India and China leading the charge. But the Indian, Chinese and Philippino governments are proposing to increase price controls on medicines, and lax intellectual property laws across the region could hinder growth.
